Montfort, Anne
Dufau, Carine
Colacios, Céline
Andrieu-Abadie, Nathalie
Levade, Thierry
Filleron, Thomas
Delord, Jean-Pierre
Ayyoub, Maha
Meyer, Nicolas
Ségui, Bruno http://orcid.org/0000-0002-6119-1889
Funding for this research was provided by:
Bristol-Myers Squibb (N/A)
Bristol-Myers Squibb (N/A)
Rotary Toulouse clubs (N/A)
Fondation Toulouse Cancer Santé (N/A)
Association pour la recherche sur le cancer (N/A)
Ligue régionale contre le cancer (N/A)
Cancéropôle grand Sud-Ouest (N/A)
Prestige co-financing grant award (N/A)
Article History
Received: 30 August 2019
Accepted: 30 October 2019
First Online: 14 November 2019
Ethics approval and consent to participate
: Each patient enrolled in the TICIMEL clinical trial is informed and consents to participate to this trial. The TICIMEL protocol has been approved by the French committees “Comité de protection des personnes” and “Agence Nationale du Médicament et des Produits de Santé”.
: All authors consent for publication of this manuscript.
: N.M. and J.P.D. have worked as investigators and/or consultants and/or speakers for: BMS, MSD, Amgen, Roche, GSK, Novartis, Pierre Fabre, AstraZeneca. B.S. has worked as an investigator, consultant and speaker for BMS. M.A. has worked as consultant and/or speaker for: AstraZeneca, BMS and Pierre Fabre. The authors declare that they have no other conflict of interest.